We believe that the Johns Hopkins entrepreneurial ecosystem has traditionally been underfunded. We set out to enable our alumni and affiliates to build world class companies.
Founded in 2015, A-Level Capital is a student-run venture capital firm that aims to empower Johns Hopkins University's entrepreneurial community through funding and support.
Our student team and professional advisors bring diverse perspectives to the investment process.
A-Level portfolio companies are transforming their industries. Take a look at some of our standouts.
Sherlock Biosciences aims to disrupt diagnostics by providing accurate, actionable health information wherever and whenever it is needed.
A modern financial membership that combines access to a personal financial advisory team backed by a powerful robo-platform.
Though our investment thesis is industry-agnostic, we have a hyper-focused vision: to foster a greater entrepreneurial ecosystem at Johns Hopkins. Our impact is omnidirectional.
We serve our alumni and affiliates by deploying much-needed capital to their upstart businesses. For some of our portfolio companies, A-Level Capital was their first check. Many have gone on to raise at exponentially higher valuations.
Through our portfolio, we help Johns Hopkins undergraduate students land internships at top-tier startups. The benefit is twofold: the JHU student body gains formative experiences in the startup world, while our portfolio companies gain premier talent in their hiring pipelines.
The student team obtains exposure to the traditionally low-access venture capital space and builds practical experience while cultivating a once-in-a-lifetime professional network.
Using strong inbound and outbound deal flows, the student team identifies companies led by Johns Hopkins alumni and affiliates.
The team undertakes a due diligence process to analyze sourced companies through correspondence with founders and confounding research. Diligence materials are forwarded to our advisors and an investment decision is made.
If a fit is determined, the team deploys capital and continues to support its portfolio companies with top-tier interns and a rich professional network of investors and advisors.
Elemy, a provider of in-home pediatric and behavioral care, has vaulted to unicorn status after raising $219 million in a funding round led by SoftBank Vision Fund 2.
The massive round is reflective of a recent breakthrough for the company: proof that its AI-based platform can create a new target for a disease, develop a bespoke molecule to address it, and begin the clinical trial process.